$ALXN Tale of the Tape

0
1085

Alexion (ALXN) Misses on Q2 Earnings, Revises Outlook – Tale of the Tape

Alexion Pharmaceuticals (ALXN) focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is sole marketed product of this Cheshire, CT based company.

In this scenario, investor focus remains on Soliris performance and pipeline progress. Alexion is expecting seven product approvals through 2018 including Strensiq, Kanuma and Soliris’ label expansion into indications such as antibody-mediated rejection, neuromyelitis optica and the prevention of delayed graft function in renal transplant patients.

Alexion has a mixed earnings track record with the company delivering positive earnings surprises in one of the last four quarters.

LEAVE A REPLY

Please enter your comment!
Please enter your name here